mitoxantrone has been researched along with Central Nervous System Diseases in 3 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Central Nervous System Diseases: Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty-one adult patients with high-risk myelodysplastic syndromes (MDS) were enrolled in a prospective randomized double-blind placebo-controlled trial evaluating the efficacy of sequential high-dose Ara C/mitoxantrone chemotherapy with or without GM-CSF." | 5.08 | S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes. ( Aul, C; Balleisen, L; Bennett, J; Büchner, T; Hiddemann, W; Hinrichs, H; Koch, P; Rowe, JM; Verbeek, W; Wörmann, B, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Verbeek, W | 1 |
| Wörmann, B | 1 |
| Koch, P | 1 |
| Aul, C | 1 |
| Hinrichs, H | 1 |
| Balleisen, L | 1 |
| Rowe, JM | 1 |
| Bennett, J | 1 |
| Büchner, T | 1 |
| Hiddemann, W | 1 |
| Laporte, JP | 1 |
| Godefroy, W | 1 |
| Verny, A | 1 |
| Gorin, NC | 1 |
| Najman, A | 1 |
| Duhamel, G | 1 |
| Lakhani, AK | 1 |
| Zuiable, AG | 1 |
| Pollard, CM | 1 |
| Milne, A | 1 |
| Treleaven, J | 1 |
| Powles, RL | 1 |
1 trial available for mitoxantrone and Central Nervous System Diseases
| Article | Year |
|---|---|
S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillus; Blo | 1997 |
2 other studies available for mitoxantrone and Central Nervous System Diseases
| Article | Year |
|---|---|
Intrathecal mitozantrone.
Topics: Anthraquinones; Central Nervous System Diseases; Humans; Injections, Spinal; Lymphoma, Non-Hodgkin; | 1985 |
Paraplegia after intrathecal mitozantrone.
Topics: Adult; Antineoplastic Agents; Central Nervous System Diseases; Humans; Injections, Spinal; Leukemia, | 1986 |